Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Treasury Shares (2021 - 2025)

Bolt Biotherapeutics' Treasury Shares history spans 3 years, with the latest figure at $52533.0 for Q4 2023.

  • For Q4 2023, Treasury Shares fell 56.89% year-over-year to $52533.0; the TTM value through Dec 2023 reached $52533.0, down 56.89%, while the annual FY2023 figure was $52533.0, 56.89% down from the prior year.
  • Treasury Shares for Q4 2023 was $52533.0 at Bolt Biotherapeutics, down from $121867.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $336000.0 in Q4 2021 and bottomed at $52533.0 in Q4 2023.
  • The 3-year median for Treasury Shares is $121867.0 (2022), against an average of $170133.3.
  • The largest annual shift saw Treasury Shares plummeted 63.73% in 2022 before it plummeted 56.89% in 2023.
  • A 3-year view of Treasury Shares shows it stood at $336000.0 in 2021, then tumbled by 63.73% to $121867.0 in 2022, then tumbled by 56.89% to $52533.0 in 2023.
  • Per Business Quant, the three most recent readings for BOLT's Treasury Shares are $52533.0 (Q4 2023), $121867.0 (Q4 2022), and $336000.0 (Q4 2021).